- Details
- Written by Super User
- Category: Info
PROGRAM
For more information about the event, please download the program !
Download the program 2018
NETWORKING WITH START-UPS
For more information about the start-ups, please download the booklet !
Download the start-ups' booklet
Download the start-ups' booklet
- Details
- Written by Super User
- Category: Info
Building upon the success of the Cohort Innovation Days held in Paris in 2014 and 2016, ARIIS (Alliance for Research and Innovation in Health Industries) and Aviesan (French National Alliance for Life Sciences and Health) organize a third Cohort Innovation Day on October 3rd, 2018 in "Station F", Paris.
This new edition will focus on cohorts and artificial intelligence.
This one-day event will be composed of 2 main parts:
- In the morning: debates with cutting-edges experts crossing the fields of artificial intelligence and cohorts
- In the afternoon: B2B meetings between industries and cohort project leaders to develop new private/public partnerships
PROGRAM
For more information about the event, please download the program !
Download the program 2018
NETWORKING WITH START-UPS
For more information about the start-ups, please download the booklet !
Download the start-ups' booklet
Download the start-ups' booklet
- Details
- Written by Super User
- Category: Info
Organizing committee
Zeina ANTOUN, GSK
Vanessa BESSON-DUBOURG, INSERM TRANSFERT
Alice BOUSSELET, INSERM TRANSFERT
Mireille CARALP, INSERM TRANSFERT
Aurélie DEFAUX, ARIIS
Sylvain DURRLEMAN, Aviesan/ITMO Santé Publique
Marco FIORINI, ARIIS
Véronique FOUINAT, ARIIS
Jean-Marie GAGLIOLO, Aviesan/ITMO Santé Publique
Anne HAZIZA, ARIIS
Industrials members of steering committee
BATAMAN-ONAL Yasemin, Sanofi Pasteur
BEZIZ Dan, Lilly
CHEVALIER Marie-Pierre, Pfizer
DELONCA Jean, Shire
DUBOIS Frédéric, Servier
FAUCONNIER Laurence, Stago
JULLIAN Nathalie, Ipsen
LESAGE Sabrina, Pfizer
LONGIN Juliette, Merck
NACHBAUR Gaëlle, GSK
PETIT-NIVARD Jean-Frédéric, Roche
SALZMAN Valérie, Servier
THEVENON Julien, Janssen France / Johnson & Johnson
THOMAS-DELECOURT Florence, AstraZeneca
TIREL Anny, MSD
Set up in April 2009, Aviesan was created out of a desire to improve French research performance by promoting consistency, creativity and excellence. This mission calls for scientific coordination of the main research themes, as well as operational coordination of projects, resources and funding.
More precisely, the purposes of Aviesan are to:
- - coordinate the strategic analysis, scientific programming and operational implementation of life and health science research
- - give a fresh boost to translational research by speeding up the transfer of fundamental knowledge to clinical application
- - increase cross-disciplinarity by opening biology and medicine up to contributions from mathematics, physics, chemistry, information technology, engineering sciences, human and social sciences
- - ensure that projects are consistent in thematic and infrastructure terms
- - carry out clinical, economic and social promotion of knowledge, particularly by facilitating industrial partnerships
- - define shared standpoints in terms of European research and international cooperation
- - harmonize and cut down on red tape for laboratories so as to free up the creativity and excellence of teams
These objectives are performed within 10 thematic multi-organization institutes (ITMOs) whose primary role is to chair the strategic debates within their own scientific community.
AVIESAN - French National Alliance for Life Sciences and Health
Created in 2010, ARIIS has three main objectives:
- FACILITATOR: one of the main missions of ARIIS is to facilitate the development of innovation by breaking down barriers in private research and increasing cross-fertilization between the fields of pharmaceutical, medical technologies, diagnostic and biotechnologies. ARIIS is convinced that building a propitious framework for innovation will help bringing ideas to the market and, therefore, to the patient.
- BRINGING TOGETHER: Aware of challenges that still have to be taken up by the health sector (cancers, infectious diseases, neurodegenerative or cardiovascular diseases, etc.), ARIIS aims to interact with all stakeholders and gather them. Thus, ARIIS federates about forty compagnies in the fields of human drugs, medical devices, diagnostic, healthcare and digital technologies around a common goal: put the patient at the core of research/innovation system.
- AMBASSADOR: ARIIS is the first national alliance in the world that federates health industry stakeholders and is a major tool for giving France competitiveness and attractiveness. The « Strategic Council of Health Industries » highlighted two clear lines of work: develop biotechnologies for the benefit of the population and reinforce partnerships between public and private sectors in biomedical research. ARIIS intends to be an ambassador of these objectives and play a fully-fledged role, especially with the Cohort Innovation Day.